DAHANCA 19: a randomized study of the importance of the EGFr inhibitor zalutumumab for the outcome after primary curative radiotherapy for squamous cell carcinoma of the head and neck.

Trial Profile

DAHANCA 19: a randomized study of the importance of the EGFr inhibitor zalutumumab for the outcome after primary curative radiotherapy for squamous cell carcinoma of the head and neck.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2016

At a glance

  • Drugs Zalutumumab (Primary)
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 02 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Jun 2011 Planned end date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 20 Dec 2007 Status changed from initiated to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top